Bone Biologics Toekomstige groei

Future criteriumcontroles 0/6

Bone Biologics zal naar verwachting dalen met 30.7% per jaar. De winst per aandeel zal naar verwachting groeien met 55% per jaar.

Belangrijke informatie

30.7%

Groei van de winst

55.0%

Groei van de winst per aandeel

Biotechs winstgroei	28.5%
Inkomstengroei	n/a
Toekomstig rendement op eigen vermogen	n/a
Dekking van analisten	Low
Laatst bijgewerkt	15 Nov 2024

Recente toekomstige groei-updates

Recent updates

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Jun 07

Bone Biologics prices $5.1M underwritten public offering

Oct 07

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Mar 18

Winst- en omzetgroeiprognoses

NasdaqCM:BBLG - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
12/31/2026	N/A	-4	N/A	N/A	1
12/31/2025	N/A	-4	N/A	N/A	1
12/31/2024	N/A	N/A	N/A	N/A	1
9/30/2024	N/A	-7	-5	-5	N/A
6/30/2024	N/A	-5	-7	-7	N/A
3/31/2024	N/A	-6	-10	-10	N/A
12/31/2023	N/A	-9	-10	-10	N/A
9/30/2023	N/A	-7	-9	-9	N/A
6/30/2023	N/A	-6	-7	-7	N/A
3/31/2023	N/A	-5	-4	-4	N/A
12/31/2022	N/A	-1	-4	-4	N/A
9/30/2022	N/A	-3	-2	-2	N/A
6/30/2022	N/A	-2	-2	-2	N/A
3/31/2022	N/A	-2	-2	-2	N/A
12/31/2021	N/A	-2	-1	-1	N/A
9/30/2021	N/A	-2	-1	-1	N/A
6/30/2021	N/A	-2	-1	-1	N/A
3/31/2021	N/A	-2	0	0	N/A
12/31/2020	N/A	-2	0	0	N/A
9/30/2020	N/A	-2	-1	-1	N/A
6/30/2020	N/A	-2	-1	-1	N/A
3/31/2020	N/A	-3	-2	-2	N/A
12/31/2019	N/A	-3	-3	-3	N/A
9/30/2019	N/A	-4	-4	-4	N/A
6/30/2019	N/A	-4	-5	-5	N/A
3/31/2019	N/A	-4	-4	-4	N/A
12/31/2018	N/A	-4	-4	-4	N/A
9/30/2018	N/A	-6	-4	-4	N/A
6/30/2018	N/A	-8	N/A	-3	N/A
3/31/2018	N/A	-6	N/A	-3	N/A
12/31/2017	N/A	-7	N/A	-3	N/A
9/30/2017	N/A	-14	N/A	-4	N/A
6/30/2017	N/A	-16	N/A	-5	N/A
3/31/2017	N/A	-22	N/A	-6	N/A
12/31/2016	N/A	-26	N/A	-7	N/A
9/30/2016	N/A	-24	N/A	-7	N/A
6/30/2016	N/A	-23	N/A	-7	N/A
3/31/2016	N/A	-19	N/A	-6	N/A
12/31/2015	N/A	-14	N/A	-4	N/A
9/30/2015	N/A	-7	N/A	-4	N/A
6/30/2015	N/A	-6	N/A	-4	N/A
3/31/2015	N/A	-6	N/A	-3	N/A
12/31/2014	N/A	-4	N/A	-3	N/A
9/30/2014	N/A	-4	N/A	-1	N/A
6/30/2014	N/A	-1	N/A	0	N/A
3/31/2014	N/A	-1	N/A	0	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat BBLG de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat BBLG de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat BBLG de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: Er zijn onvoldoende gegevens om te bepalen of de omzet van BBLG naar verwachting sneller zal groeien dan de markt US.

Hoge groei-inkomsten: Er wordt verwacht dat BBLG volgend jaar geen omzet zal hebben.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Onvoldoende gegevens om te bepalen of het rendement op eigen vermogen van BBLG naar verwachting over 3 jaar hoog zal zijn

Bone Biologics Toekomstige groei

Future criteriumcontroles 0/6

Belangrijke informatie

Recente toekomstige groei-updates

Price target decreased to US$4.88

Price target decreased to US$4.88

Recent updates

New major risk - Financial position

Bone Biologics Corporation Appoints Phillip Meikle to Board of Directors

Bone Biologics Corporation Announces Resignation of Don Hankey as Director, Effective Immediately

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $1.143121 million.

Bone Biologics Corporation, Annual General Meeting, Sep 17, 2024

New major risk - Share price stability

Bone Biologics Corporation Announces First Two Patients Treated in Pilot Clinical Study with Bone Biologics NB1 Bone Graft Device in Spine Fusion

Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $1.99934 million.

Bone Biologics Corporation has completed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Bone Biologics Corporation has filed a Follow-on Equity Offering.

Bone Biologics Corporation Announces Board Changes

Bone Biologics Regains Compliance with Nasdaq Continued Listing Requirements

Bone Biologics Corporation has completed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation has filed a Follow-on Equity Offering in the amount of $0.729 million.

Bone Biologics Corporation Receives Non-Compliance Notice From Nasdaq

New major risk - Financial position

Bone Biologics Corporation, Annual General Meeting, Sep 12, 2023

New major risk - Share price stability

Companies Like Bone Biologics (NASDAQ:BBLG) Are In A Position To Invest In Growth

Nasdaq Notifies Bone Biologics Regarding Non-Compliance with the Minimum Bid Price Requirement

Bone Biologics Corporation Resigns Stephen Laneve as Director

Bone Biologics Receives Written Notice from the NASDAQ Regarding Minimum Bid Price Requirement

Price target decreased to US$4.88

Price target decreased to US$4.88

Bone Biologics Corporation has completed a Composite Units Offering.

Bone Biologics Corporation has completed a Composite Units Offering in the amount of $5.1 million.

Bone Biologics prices $5.1M underwritten public offering

Bone Biologics Corporation, Annual General Meeting, Aug 23, 2022

We're Not Very Worried About Bone Biologics' (NASDAQ:BBLG) Cash Burn Rate

Less than half of directors are independent

Winst- en omzetgroeiprognoses

Toekomstige groeivoorspellingen analisten

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Ontdek groeibedrijven